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At least 25% of coronary patients have sudden death ornonfatal myocardial infarction without prior symptoms.1
Therefore, the search for coronary patients with subclinical
disease who could potentially benefit from intensive primary
prevention efforts is critically important. The American Heart
Association’s (AHA) Prevention V Conference, “Beyond
Secondary Prevention: Identifying the High Risk Patient for
Primary Prevention,” addressed ways to identify more pa-
tients who are asymptomatic and clinically free of coronary
heart disease (CHD) but at sufficiently high risk for a future
coronary event to justify more intensive risk reduction ef-
forts.2 In this report, we amplify on key findings and
recommendations of the AHA Prevention V conference,
highlight new research since the conference, and propose an
approach to the use of office-based testing and additional
noninvasive procedures in selected patients to better define
their coronary event risk. The recommendations are concor-
dant with the recently released approach to risk assessment
and management from the third report of the Adult Treatment
Panel of the National Cholesterol Education Program
(ATP-III).3
Enthusiasm for primary prevention and risk assessment in
asymptomatic people has been spurred by recent advances in
prevention research. Lipid-lowering trials demonstrated that
primary prevention of coronary events is feasible, evidenced
by the West of Scotland Coronary Primary Prevention Study
(WOSCOPS) trial4 of hypercholesterolemic men and by the
Air Force/Texas Coronary Atherosclerosis Prevention Study
(AFCAPS/TexCAPS) trial5 in average or typical risk men and
women with only moderate lipid abnormalities. Aspirin6 or
ACE inhibitors7 can also reduce risk in selected asymptom-
atic, high-risk people. Emerging coronary risk factors have
been described including inflammatory, infectious, and
thrombotic markers,8 and there has been a steady flow of
reports that focus attention on potential new ways of predict-
ing coronary risk.9 In addition, noninvasive tests for subclin-
ical atherosclerotic disease are available and becoming
widely promoted for risk assessment in asymptomatic pa-
tients. Accordingly, the Prevention V Conference examined
whether current techniques or a combination of tests can
optimize or improve risk assessment for primary prevention
of CHD.
A primary recommendation of the Prevention V Confer-
ence was that risk assessment begins in the physician’s office,
where all adults should undergo an office-based risk assess-
ment as the initial step in predicting risk to identify those
needing more intensive risk reduction. Numerous approaches
(Table) are available for office-based risk assessment,9–11 but
none is yet considered ideal.9,12 However, as a first approxi-
mation of risk prediction, office-based measures are essential
to begin the process of selecting patients for further interven-
tion or additional testing. One approach endorsed by both the
AHA and the American College of Cardiology (ACC) is a
determination of “global risk” as measured by a multifactorial
statistical model such as the Framingham Risk Score.13
Well-established risk factors including age, sex, smoking
history, blood pressure, total serum cholesterol, HDL choles-
terol, and blood glucose (or history of diabetes) are measured
and entered into a risk calculation model. The procedure can
be paper-based3,14 or computer-based3,13 and results in an
estimation of relative risk and absolute risk of a cardiac event
in the near term (eg, 10 years). The AHA offers materials to
assist physicians in the performance of this task,13 and “global
risk assessment” by these methods is more quantitative than
use of categoric risk factors alone.15 Newer risk factors not
included in standard office-based tools, such as homocys-
teine, C-reactive protein, and lipoprotein (a), were considered
at the Prevention V Conference2,8; however, none emerged as
a convincing means of improving office-based risk assess-
ment. Advice to perform an initial risk assessment in all
patients is consistent with current clinical practice guidelines
including ATP-III3 and Joint National Committee on Preven-
tion, Detection, Evaluation, and Treatment of High Blood
Pressure (JNC)-VI,16 with European Guidelines11 and with
AHA/ACC recommendations.13
After a patient has been assessed for absolute coronary risk
in the doctor’s office, the next step is to use this information
to determine appropriate interventions including reassurance
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of low-risk patients or further testing when estimated risk
level does not provide clear clinical direction. We propose
that asymptomatic patients fall into 3 reasonably distinct
categories at this point in assessment (Figure 1). In one
category are patients who have a low Framingham risk score
and no identifiable CHD risk factors (nonsmoking, total
cholesterol #200 mg/dL, HDL cholesterol .40 mg/dL,
systolic blood pressure ,120 mm Hg, diastolic blood pres-
sure ,80 mm Hg, no evidence of glucose intolerance, body
mass index ,25 kg/m2, and no family history of premature
atherosclerotic vascular disease). These people are at low risk
of coronary events both short-term10 and long-term17 and can
be reassured about their risk status without further risk
assessment testing. We estimate that this “low-risk” group
constitutes approximately 35% of the US adult population 20
years of age and over.18 In the short-term, they can be offered
general public health recommendations, and they can usually
avoid further risk assessments for approximately 5 years.3 On
the basis of Framingham data,10 these patients have an
absolute risk for “hard CHD” of less than 5% to 6% in 10
years. Hard CHD is defined in the Framingham Heart Study
as recognized and unrecognized myocardial infarction, coro-
nary insufficiency, and coronary heart disease death.10
At the other end of the risk spectrum, following office-
based assessment in asymptomatic people, a second category
of patients can be identified as “high-risk.” These patients can
have established CHD, other clinical forms of atherosclerotic
disease, type 2 diabetes, or are older patients with multiple
other CHD risk factors. Some patients may be at high risk
because of extreme elevations of serum cholesterol or blood
pressure. In accordance with ATP-III3 or JNC-VI16 guide-
lines, high-risk asymptomatic people should have all CHD
risk factors treated to reduce CHD and total cardiovascular
disease risk. On the basis of a recent analysis of National
Health and Nutrition Examination Survey (NHANES) III
data, approximately 25% of US adults belong in this “high-
risk” category.18 Thus, at the 2 ends of the spectrum (low risk
or definitely high risk), we estimate that approximately 60%
of the US adult population can be risk-stratified and further
treated without additional assessments beyond an office-
based risk analysis. According to Framingham data,13 high-
risk patients would typically have a risk for “hard CHD”
events greater than 2% per year and frequently greater than
3% per year, similar to that seen in patients with prior CHD
events.10,19 In concert with new ATP-III guidelines, risk
factor targets should be identical in these patients to the
AHA’s secondary prevention guidelines.20 Such patients
either have CHD or are considered to have a CHD risk
equivalent.3
The third category of patients following the office-based
assessment falls in a risk zone intermediate between the
categories described above. This is a sizable group, judging
from NHANES III data, roughly 40% of the US adult
population.18 Patients in the intermediate risk group do not
currently qualify for the most intensive risk factor interven-
tions,20 yet they have 1 or more risk factors that exceed
desirable levels. Such patients should be counseled about
their intermediate CHD risk and offered general dietary and
life habit advice that might influence them to change behav-
iors and achieve low-risk status in the future. Some
intermediate-risk patients also will be candidates for choles-
terol-lowering drugs. Intermediate-risk patients could benefit
Examples of Approaches to Risk Assessment With Multiple
Coronary Heart Disease Risk Factors*
National Cholesterol Education Program Guidelines (NCEP)
European Societies of Cardiology, Atherosclerosis, and Hypertension
Framingham Risk Score
British Regional Heart Study (BRHS) Risk Score
Sheffield Coronary Risk Tables
GREAT (General Rule to Enable Atheroma Treatment)
Munster Heart Study (PROCAM) Risk Score
Dundee Coronary Risk Disc
National Heart Foundation of New Zealand Guidelines
West of Scotland Cardiovascular Event Reduction Tool (CERT)
*Derived from References 9 and 34.
Figure 1. Flow chart.
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most from further risk stratification testing, if such testing is
feasible, practical, targeted, and effective at further defining
risk or in motivating effective behavioral changes.
There is evidence to support the use of various noninvasive
tests of silent ischemia and/or of subclinical vascular occlu-
sive disease in the intermediate-risk population. Relevant
literature was reviewed in the Prevention V Conference,21,22
and it was concluded that “selected patients” should have
further testing if initially found to be at intermediate risk.
Boundaries for selecting such patients were not clearly
defined in the Prevention V Conference. New research results
published since the Prevention V Conference add support to
this approach to selective use of noninvasive testing to
enhance risk assessment.
Ankle-brachial index (ABI), the ratio of systolic blood
pressure in the ankle arteries to the systolic blood pressure in
the brachial arteries, provides incremental prognostic utility
over traditional risk factors, at least in patients older than 60
years of age. The ABI is considered a reliable sign of
peripheral arterial disease when it is ,0.90. Patients with
symptomatic peripheral arterial disease, that is, those with
intermittent claudication, are well known to have markedly
increased risks of CHD events and of other cardiovascular
disease (CVD) events (up to 15-fold increased in one
study23). In population studies, asymptomatic individuals
with low ABI also have been found to have markedly
increased CHD and total-CVD risks. For example, in a
long-term, prospective study, primarily asymptomatic men
and women with an average age of 66 years and a low ABI
value (,0.90) had a relative risk of 6.3 for all cardiovascular
disease mortality, 4.8 for coronary disease mortality alone,
and 3.1 for all-cause mortality. High relative risks persisted
after adjustment for standard CVD risk factors considered in
the Framingham Risk Score.23 These relative risks are simi-
lar, in the primary prevention setting, to relative risks seen in
secondary prevention.19,20 We judge this level of risk to be
considerable enough to move a patient with apparent “inter-
mediate risk,” based on office risk assessment to high-risk
status. An abnormal ABI, in an otherwise asymptomatic
patient, provides incremental prognostic information, espe-
cially in people older than 60 years of age or in smokers. The
ABI could therefore be useful in refining risk prediction in
these categories of intermediate-risk patients. It is inexpen-
sive but not yet widely available outside of vascular labora-
tories. It could potentially be used, in selected patients, in the
office setting.
Carotid B-mode ultrasound, with emphasis on intima-
media thickness (IMT), can also yield incremental risk
stratification information. The examination is performed
bilaterally on the distal straight 1 cm of the extracranial
common carotids, the carotid bifurcations, and the proximal 1
cm of the internal carotids. Several carefully conducted
studies24–26 in asymptomatic people older than 50 years of
age demonstrated that abnormal IMT values result in relative
risks as high as 5.0, over and above traditional coronary risk
factors, for occurrence of future cardiovascular (stroke or
myocardial infarction) events. Again, this level of relative
risk is similar to that seen in secondary prevention and has
therefore been termed “a coronary risk equivalent” to signify
that the risk for future events is similar to that seen in the
coronary patient.3,19 Thus, carotid ultrasonography may also
improve risk assessment in intermediate-risk patients, espe-
cially in those older than 50 years of age. However, one
caveat must be stated. The carotid ultrasound examination for
IMT measurement is not routinely performed in clinical
ultrasound examinations, and the best-validated predictive
value of carotid IMT derives exclusively from highly quality-
controlled research laboratories. It is not clear that a similar
quality of IMT measurements can be derived in the majority
of clinical ultrasound laboratories.
Recent work suggests that electron-beam tomography
(EBT) can also improve risk prediction in intermediate-risk
patients.27 In a cohort of 1172 asymptomatic men and women
(mean age, 53 years) who were self-referred for EBT, with
average follow-up 3.6 years, 39 subjects had a coronary
event, including 3 coronary deaths, 15 nonfatal myocardial
infarctions, and 21 coronary artery revascularizations. For a
coronary calcium score of $80, sensitivity for prediction of
one of these coronary events was 0.85 with specificity 0.75.
Thus, with a prior probability of a coronary event in the
intermediate range (.6% in 10 years but ,20% in 10 years),
a calcium score $80 would yield a posttest probability in
virtually all such patients greater than 2% per year, that is, a
level similar to that in secondary prevention, or a “coronary
risk equivalent.” Therefore, positive EBT test results could be
useful in further risk stratification for the intermediate-risk
patient. Figure 2 demonstrates how a pretest-estimated risk of
6% in 10 years (derived from initial office-based testing) can
move up to a posttest probability of .20% in 10 years when
the EBT calcium score is at least 80 (per data from Arad
et al).27
Despite conventional teaching to the contrary, exercise
stress testing in asymptomatic men can also yield prognostic
information that permits refined risk stratification in
intermediate-risk patients.28 A recent report illustrates this
point in a population of 25 927 healthy men (mean age, 42.9
years) free of clinical cardiovascular disease who underwent
maximal exercise stress testing in the context of a preventive
health evaluation.28 With an end point of CHD death, an
abnormal maximal exercise stress test yielded an age-
adjusted relative risk of 21 in patients with no major coronary
risk factors. Relative risks ranged from 8 to 10 in patients
with 1, 2, or 31 coronary risk factors compared with similar
patients with normal exercise test results. Similarly useful
prognostic results have been reported in at least 2 other
studies of asymptomatic men with coronary risk factors.29,30
Thus, in a manner similar to that seen with EBT, carotid
ultrasound, or ABI, an abnormal exercise stress test can
advance a patient’s risk status from intermediate to high risk.
Conversely, a negative test in the intermediate-risk male
patient can lower the patient’s risk status to a level at which
greater reassurance can be provided and less intensive risk
factor intervention more confidently advised. Exercise stress
testing can therefore be considered as another means of
further risk-stratifying the intermediate-risk male patient after
an office-based assessment. Unfortunately, similar data are
not available in women.2
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A few patient examples illustrate these points. Consider a
52-year-old asymptomatic male smoker with a blood pressure
level of 155/90, total serum cholesterol of 240 mg/dL, HDL
cholesterol of 37 mg/dL, and normal fasting blood glucose. The
first step is to perform an office-based risk assessment with these
data. With the use of the AHA Risk Calculator,13 this person’s
risk falls into the high-risk category (by AHA risk calculator,
risk is estimated at 20% in 10 years for hard CHD). He is
therefore a candidate for intensive risk factor modification, and
further noninvasive assessment is not required to define the need
for preventive therapies or the goals of such treatment.
A second case illustrates how noninvasive testing could
influence patient treatment in an intermediate-risk patient.
Consider a 50-year-old asymptomatic man who does not
smoke, who has a blood pressure level of 140/85, total
cholesterol of 210 mg/dL, LDL cholesterol of 137 mg/dL,
HDL cholesterol of 32 mg/dL, a negative family history of
vascular disease, and a normal fasting blood glucose. On the
basis of Framingham risk assessment scoring,13 this man’s
risk falls into the “intermediate” zone with a 9% estimated
10-year risk of hard CHD (refer to Figure 1). Although he
does not fall into the high-risk category requiring intensive
intervention,20 his LDL cholesterol level is not optimal, and
blood pressure is also not optimal. If further testing were done
in this person, for example EBT, and a coronary calcium
score of $80 were found, the physician would be able to
reassign him to a higher risk category (at least 20% in 10
years) and justifiably proceed more aggressively to reduce his
risk factors that are present. Specifically, given that this
hypothetical patient’s estimated risk is equivalent to that of a
typical coronary patient, we propose the need for intensive
intervention.20 If the calcium score were zero (as it would be
in 35% of men his age), the physician should still counsel the
patient about trying to control his risk factors for the long
term, but one would not be justified to intervene with costly
lipid-lowering or blood pressure–lowering drugs at this time,
based on a revised (posttest) risk estimate of approximately
1.9% in 10 years. Although this illustration used EBT, an
alternative test might have been a stress ECG28; however,
because of his relatively young age, this 50-year old man
would not be an exceptionally good candidate for carotid
ultrasound or ABI because of the relatively low likelihood of
positive tests in this age group.
A prominent feature of risk estimation by means of the
Framingham equation is the progressive increase in absolute
risk with advancing age. Undoubtedly, this increase reflects
the cumulative nature of atherogenesis. The powerful effect
of age in risk prediction denotes the higher risk for major
coronary events present in persons with more advanced
atherosclerotic disease. Nonetheless, a single age score will
mask the extent of variability in risk resulting from differ-
ences in plaque burden in older individuals. To apply average
risk scores for age to individual patients may lead to miscal-
culation of true risk, particularly because Framingham applies
so much weight to age as a risk factor. Especially in older
persons, Framingham-based risk estimates could lead to
inappropriate selection of patients for aggressive risk-
reduction therapies. This fact points to the need for flexibility
and the application of clinical judgment in adapting treatment
guidelines for persons 65 years of age and older. The use of
noninvasive testing for subclinical atherosclerotic disease
appears to be promising for risk assessment in older persons.
The extent of atherosclerotic plaque burden, or presence of
subclinical ischemia, may be a better way to select such
persons for aggressive risk factor intervention than measures
of risk factors, some of which have diminished power to
predict CHD in this age range.31
The goal of improved risk assessment is a more selective
approach to the use of noninvasive cardiovascular studies and of
preventive interventions such as lipid lowering, aspirin, or ACE
inhibition. It must be understood clearly that an abnormal
noninvasive test result in an intermediate-risk, asymptomatic
person should be interpreted as yet another risk factor for a
future cardiovascular event and not as a mandate for diagnosis of
the presence or absence of angiographic coronary artery disease.
Test results in an asymptomatic person must not be confused
with apparently similar test results in symptomatic patients in
whom proper management of CHD is the goal of testing—as
opposed to enhanced risk assessment and selective use of
preventive interventions as described here. Noninvasive testing
for improved risk assessment has been greeted cautiously by
critics in part because of the inappropriate response to test results
inherited from the cardiologic workup of symptomatic patients.
It is crucial that the use of such tests used to improve assessment
Figure 2. Example of how a noninvasive test result could substan-
tially modify probability estimates of a CHD event. Pretest probabil-
ity (x-axis) is estimated (see References 9 and 12) by standard
CHD risk factor measurements and one of the available multivari-
ate models for quantification of probability of a future CHD event
(pretest probability). Posttest probability (y-axis) is different from
pretest estimate whenever sensitivity and specificity are not each
50% (line of identity shown as hatched line). In this example, post-
test probability is different from pretest probability, and values differ
markedly, depending on whether the noninvasive test result is pos-
itive (solid line) or negative (dashed line). On the basis of sensitivity
and specificity data from Arad et al,27 test sensitivity is assumed to
be 0.85 and test specificity is assumed to be 0.75. Similar graphs
can be plotted for each of the noninvasive tests reviewed here by
sensitivity and specificity data from the literature. Note that a
threshold of 20% in 10 years (see text) is crossed in this example
when pretest probability is .6% in 10 years and noninvasive test
result is positive. On the other hand, a negative test result mark-
edly reduces predicted CHD risk estimate within the pretest range
of probabilities shown (intermediate pretest risk).
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of prognosis not be confused with the use of such tests for
coronary disease diagnosis.
In conclusion, primary prevention measures are available,
effective, and relatively safe. Emphasis has shifted substantially
in the past few years from a question of whether to treat patients
in the primary prevention setting to the matter of selection of the
highest-risk patients to maximize the benefit/cost ratio of treat-
ments.32 The AHA Prevention V Conference suggested the
potential for more routine use of office-based risk assessment for
initial patient stratification.33 Several noninvasive tests are al-
ready available, in our judgment, that should be considered as a
means of further stratifying risk in a large group of apparently
intermediate-risk patients. We encourage adoption of the ap-
proaches discussed here to improve and refine the risk assess-
ment and risk reduction processes.12,34
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